Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Acurx Pharmaceuticals, Inc. (ACXP) had Normalized Income after Taxes of $-14.10M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-14.10M |
|
-- |
|
-- |
|
$14.10M |
|
$-14.10M |
|
-- |
|
$-14.10M |
|
$-14.10M |
|
$-14.10M |
|
$-14.10M |
|
$-14.10M |
|
|
Normalized Income after Taxes |
$-14.10M |
$-14.10M |
|
$-14.10M |
|
16.16M |
|
16.16M |
|
$-0.87 |
|
$-0.87 |
|
| Balance Sheet Financials | |
$3.86M |
|
-- |
|
-- |
|
$3.86M |
|
$3.24M |
|
-- |
|
-- |
|
$3.24M |
|
$0.62M |
|
$0.62M |
|
$0.62M |
|
17.03M |
|
| Cash Flow Statement Financials | |
$-10.38M |
|
-- |
|
$6.62M |
|
$7.47M |
|
$3.71M |
|
$-3.77M |
|
$3.44M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.19 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-10.38M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-2292.74% |
|
-2292.74% |
|
-365.56% |
|
-2292.74% |
|
$0.04 |
|
$-0.64 |
|
$-0.64 |
|